CD86 and neoplasm: A B-cell subset expressing activation markers (CD25+CD69+B7-H1+CD81+CD86+) and termed tumour-evoked Bregs (tBreg) induced the generation of Foxp3+Tregs, which inhibited anti-tumour responses [22].